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HYPERTHERMIA, RADIATION AND CHEMOTHERAPY:

THE ROLE OF HEAT IN MULTIDISCIPLINARY CANCER CARE
MARK HURWITZ M.D.
PAUL STAUFFER MS, MSEE

HISTORICAL BACKGROUND
The therapeutic potential of heat has been recognized for nearly 5000 years. The first recorded use of
medicinal heat dates back to the 27th century B.C. in Egypt where direct application of hot blades or
sticks were used to ablate breast cancer.(1) There are reports of various therapeutic uses of heat in
ancient China and India as well.(2) The ancient Greeks recognized the therapeutic value of moderate
temperature elevations such as occurs with fever. In the 6th Century B.C. Paramenides stated “Give me
the power to produce fever and I will cure all diseases”.(3) Subsequently Hippocrates applied
hyperthermia to treat breast cancer. He expressed admiration for the therapeutic benefit of heat
stating; “That which drugs fail to cure, the scalpel can cure. That which the scalpel fails to cure, heat can
cure. If heat cannot cure, it must be deemed incurable.”(4) Over the ensuing several centuries there is
documented use of moderate heating to cure a variety of diseases in Greece and subsequently the
Roman Empire.(5)
In the 19th Century Busch reported successful use of infection to treat cancer and in 1893 Coley
retrospectively reviewed the cases of 38 patients with advanced cancer who developed high fevers
spontaneously or after purposeful infection with erysipelas. Thirty one of these patients experienced a
remission in their cancers including twelve with a complete clinical response.(6)

The first report of use of radiation with hyperthermia is a German phase II trial published in 1910. One
hundred patients with a variety of pathologically confirmed advanced cancer were treated with
radiation and diathermy, a technique for local heating of body tissues with electric currents. Thirty two
patients experienced complete regression while another 32 experienced temporary improvement.(7) In
1935 Warren reported on combined induced fever with roentgen therapy which resulted in significant
improvement and palliation in 29 of 32 end stage oncology patients. (8)
THERMAL BIOLOGY
Biologic Rationale For Combining Heat With Radiation and Chemotherapy

The biologic basis for benefit of hyperthermia with modern cancer therapies including radiation and
chemotherapy began to be appreciated by the 1970’s. In regards to radiation therapy, hyperthermia
was recognized as an ideal complementary treatment. Many conditions that contribute to radioresistance including hypoxia, acidification, and S-phase of the cell cycle either enhance sensitivity to
heat or do not temper it.(9-15) (FIGURE 1) Hyperthermia also typically results in enhanced perfusion that
may result in improved tumor oxygenation for subsequent radiation treatments. (16-17)
Chemosensitization with hyperthermia is dependent on the particular mechanism of effect for each
agent. The magnitude of effect ranges from none as is typical with anti-metabolites to synergistic
effects such as with cisplatin. (FIGURE 2) The mechanism of enhanced cytotoxicity can include increased
intracellular drug accumulation, inhibition of DNA repair, abrogation of cell cycling in S-phase when cells
are most sensitive to heat, enhanced free radical production, and reversal of drug resistance.(18-20))
Drugs for which synergistic effects have been noted include cisplatin, adriamycin,
bleomycin, melphalan, cyclophosphamide, nitrosoureas, nitrogen mustards, and mitomycin c.(19)
Interaction of hyperthermia with other agents including taxanes and anti-metabolites is possible
although for many agents the complex interactions that contribute to enhanced treatment effects

remain to be fully defined.(20) In regards to timing and sequencing, simultaneous administration or
chemotherapy followed immediately by hyperthermia has been shown to have the greatest effects.
Mechanism of Cell Death With Hyperthermia
High temperatures achieved with thermal ablation, typically in the range of 65-85°C result in
instantaneous cell death. Temperatures above 45°C sustained for sufficient time will lead to protein
denaturization and cell death typically via necrosis. Clinical hyperthermia involves temperature
elevations in the range of 39-45°C Within this moderate temperature elevation range, tumor cell death
occurs in a log-linear manner with an initial shoulder region followed by a steeper decline in cell survival
correlated with increasing temperatures up to 45°C. While temperatures between 42- 45°C can result in
cell death with sufficiently long exposure, use of hyperthermia alone is not a practical nor particularly
effective theraupeutic strategy as monotherapy. The primary benefit of hyperthermia with moderate
temperature elevation is therefore achieved through enhancement of anti-tumor effects through
combination with either radiation or chemotherapy.
The precise mechanisms by which moderate temperature hyperthermia results in tumor cell death are
complex and highly dependent on the heating profile. In addition to complementary biologic effects
with radiation and chemotherapy, mechanisms for direct effect include protein denaturization
including inhibition of sub-lethal and potentially lethal damage repair through inactivation of DNA repair
pathways leading to mitotic catastrophe, induction of senescence, apoptosis, and necrosis. (21-28)
Research has revealed that protein denaturization is a key biologic effect of hyperthermia at modest
temperature elevations.(29) The activation energeries for protein denaturization and heat induced cell
death were noted to be within the same range. Further research suggested that nuclear proteins are
most sensitive (30-32) and a high degree of correlation of nuclear protein aggregation and heat induced cell
kill has been noted. Radiation sensitization is achieved in large part through nuclear protein aggregation
which inhibits the DNA repair process thus converting potentially lethal radiation induced DNA breaks into
lethal events. Specifically, heat induces changes in DNA repair foci such as the MRN complex which

includes MRE11, rad 50, and nbs1, key proteins involved in double strand break repair, the nucleolus and
on the complexes that anchor DNA to the nuclear matrix thus contributing to radiosensitization. (33-34)
Chromosomal aberrations may also occur due to heat sensitivity of the centriole. (35) Failure of DNA
replication in S-Phase of the cell cycle results in mitotic catastrophe. Research to date has made it clear
however that other mechanisms including necrosis, apoptosis and senescence also have important roles in
hyperthermic cell kill. Temperatures above 44-45°C generally lead to cell death via extensive protein
denaturization and necrosis. (36). Apoptosis has been noted at more moderate temperature elevations
such at 41.5°C sustained for one to two hours. (37) Stress induced premature senescence may also occur in
response to heat shock. (38)
Heat Shock Proteins
Heat shock proteins (HSP) play a central role in hyperthermia response. Heat shock proteins (HSP), first
identified in relation to thermal stress are now recognized as ubiquitous proteins involved in general
cellular stress response and also for their role in immune modulation. HSP were discovered in 1961 by

Chanel and Maury who described the effects of thermal shock on blood proteins in fish.(39) While
initially identified in relation to heat shock and thus named as such, HSP are now known to have a
universal role in cellular stress response. In the intracellular milieu HSPs have a primary role in
stabilizing damaged proteins allowing for repair. This protective mechanism however has negative
connotations for treatments directed at killing cancer cells. This response which may last for several
days has potential to abrogate the effects of hyperthermia. This concept is referred to as thermal
tolerance. The induction of thermal tolerance has been found to be associated with HSP up
regulation.(40-41) Due to concerns about thermal tolerance, hyperthermia is typically delivered no more
than a few times per week, generally with at least 72 hours between treatments.
While serving a protective role for the cancer cell in the intracellular environment, HSP have potentially
beneficial anti-neoplastic effects in the extracellular milieu. HSPs have chaperokine effects which
include a central role in cellular immune regulation coupled with the ability to stimulate proinflammatory cytokine production.(42) HSP-PC complexes with functional CD8+ cells and macrophages
are all required for induction of immunity.(43) The chaperone function of HSP relates to their role in
shuttling immunogenic peptides onto MHCs for presentation to T cells. Notably, HSP-PC complexes can
induce tumor-specific immunity. (44-46) (FIGURE 3)
Radiation has also been shown to have similar effects in regard to immune response. In the clinical
setting, a consistent increase in serum HSP70 over the duration of a standardly fractionated course of
radiation therapy for prostate cancer patients was noted. This increase in HSP70 was associated as
expected with increase in proinflammatory cytokines and components of the cellular immune response
including CD8+ and natural killer cells. Cell and animal modeling indicated this response is consistent
with tumor specificity.(47) Optimization of immune response with combination of hyperthermia with

radiation and the ever increasing number of immunotherapeutics remains an active area of emerging
investigation.
Thermal Enhancement Ratio
The additional anti-neoplastic effect achieved with hyperthermia is referred to as the thermal
enhancement ratio or TER. TER is the ratio of radiation or chemotherapy doses required to produce a
given level of biological damage with versus without heat. The finding of a significant TER as first
defined in the laboratory has subsequently been demonstrated in clinical practice with most studies
indicating a TER of approximately 1.5. (FIGURE 4)
THERMAL PHYSICS
Mechanisms of Heating
While there are hundreds of medical devices available to administer thermal therapy, there are just
three basic mechanisms of heat delivery to tissue: thermal conduction, resistive or dielectric losses, and
mechanical losses from molecular collisions. The most fundamental mechanism of heat transfer in the
body is thermal conduction, which causes a net flow of heat energy from higher to lower temperature at
a rate dependent on the tissue thermal properties and temperature gradient.
Resistive or dielectric losses result from an applied electromagnetic (EM) field. Critical factors in selecting
appropriate EM frequency are tumor size and depth. Dielectric losses increase with frequency,
increasingly restricting tissue penetration at microwave frequencies greater than 150 MHz. Spatial
resolution (focal spot size) is approximately one half the wavelength in tissue which varies from a tumorsized 4 cm at 1000 MHz to >3 m at radiofrequencies (RF) below 100 MHz. Therefore a tradeoff exists
between RF sources that can penetrate deep in the body but cannot selectively heat small volumes

versus microwave sources that can focus energy into smaller tumors but cannot penetrate deep below
the surface.
The third mechanism of heat generation involves mechanical losses from molecular collisions as induced
by an ultrasound (US) pressure wave. Like EM energy, US attenuates exponentially with depth in soft
tissue. Furthermore, ultrasound absorption is fifty times greater in bone than soft tissue and therefore
cannot be applied when there is bone between the applicator and the target. The most useful
frequencies for power deposition in human anatomy are in the range of 0.5-10 MHz which have
wavelengths ranging from 0.1 - 3 mm. These wavelengths are much shorter than the tumor dimensions
and allow a focal spot size less than 2 mm diameter. Due to lower attenuation rate in soft tissue, US can
penetrate deeper than EM energy.
Approaches To Heating
Heating

approaches

include

whole

body,

deep-regional,

deep-focused,

superficial,

or

interstitial/intracavitary techniques. (FIGURE 5)
Whole Body Heating
Regardless of tumor location within the body, the most uniform tumor temperatures are possible by
heating the entire body. The disadvantages are systemic stress and a limitation to <42°C due to
thermosensitivity of critical tissues like heart, liver and brain. Thus the thermal goals of systemic
therapy are usually more modest than local heating techniques, and intended for activation of drugs

(48)

or enhancement of immunologic response(49-50)) rather than radiosensitization. When heating the whole
body, normal body-cooling mechanisms such as respiration and skin cooling must be blocked by
thermally insulating the patient and preheating the breathing circuit. The patient is often anesthetized
or sedated and physiologic conditions and electrolyte balance must be carefully controlled throughout

treatment which generally lasts many hours. Following early work using induced fever therapy,(51)
systemic heating is generally accomplished via thermal conduction heating from immersion in heated
fluid or air.(52-55) The heating process can be accelerated using infrared radiation.(56) For some
applications, regional heating is sufficient with invasive approaches like intraperitoneal irrigation(57) or
circulating blood that is heated by exteriorized arterio-venus shunts through organs(58) or limbs(59).
Isolated Limb and Peritoneal Perfusion
Hyperthermic limb perfusion involves isolating the limb from systemic circulation, typically with a
tourniquet, after which chemotherapy is administered, often in the range of 60 minutes with
extracorporeal circulation.(60-61) At the beginning of perfusion phase, the blood of the limb is heated
after which chemotherapy infusion begins. Therefore a high concentration of chemotherapy can be
delivered to the targeted limb while minimizing systemic toxicity. With peritoneal infusion the
chemotherapeutic agent is heated and then injected directly into the targeted region.(62-64)
Deep Regional Heating
Deep penetration of heat is best accomplished with array applicators that spread out superficial power
deposition across a large surface area and combine geometrically to produce a concentrated heat focus
at depth. The most practical approach to heat large tumor volumes at depth is the use of
electromagnetic fields in the range of 8-140 MHz. This approach takes advantage of wavelengths that
are long compared to body dimensions and thus deposit energy deeper and over a sizeable region.
Deep Focused Heating
Deep focused techniques include interstitial implantation of heatable sources into the body and more
recently injectable paramagnetic nanofluids. Alternative magnetic fields (AMF) can be used to heat
ferromagnetic seeds of fluids implanted in the body. These strategies have been investigated for

prostate cancer where placement of the heatable seeds is similar in technique to implantation of
radioactive seeds as done for prostate brachytherapy.(65-66)
Superficial Heating
To date, microwave applicators are used most frequently for heating superficial tissue disease less than
3 cm deep. In the US, the most common device is the microwave waveguide, a simple rectangular or
circular metal structure that guides EM waves from a single monopole feed out the open aperture which
is at least a half wavelength in largest dimension. Waveguide antennas are commercially available from
7.5 to 24 cm, designed for use at approved Industrial Scientific and Medical (ISM) band frequencies of
915 or 2450 MHz in the US, (67-70) or 430-434 MHz in Europe(71-72) and Asia. (73-74)
CLINICAL HYPERTHERMIA
Early Clinical Experience
Enthusiasm quickly waxed in the 1970’s and 1980’s for hyperthermia with realization of the potential for
therapeutic gain combining moderate temperate heating and radiation. The Radiation Therapy
Oncology Group initiated two phase III trials in the 1980s. These trials however were hampered by
several key limitations including the inability at that time to effectively heat many tumors with the
technology available, lack of appreciation for meaningful goals in prescribing hyperthermia, and lack of
quality assurance guidelines.
RTOG 81-04 compared radiation with or without hyperthermia for a variety of malignancies including
breast, head and neck, trunk, and extremity tumors. No difference was noted in complete response
between groups; however, benefit was noted for tumors less than 3 cm, suggesting that if tumors could
be effectively heated meaningful clinical responses could be achieved.(75) A second phase II trial, RTOG
84-19 was conducted to assess use of radiation with or without interstitial hyperthermia for persistent

or recurrent tumors after previous radiation or surgery. No difference in any of the study endpoints was
noted; however, only 1 of 173 evaluable patients met the minimum accepted criteria for adequate
hyperthermia. The authors concluded that the study ultimately failed in its objective to assess the value
of hyperthermia.(76) Coupled with other challenges including the typical hour or more needed

to

administer hyperthermia, the difficulties in administering hyperthermia and lack of standards led many
radiation oncologists to abandon pursuit of hyperthermia.
Additional Randomized Trials
Following the RTOG trial experience, over 20 randomized trials assessing hyperthermia with radiation or
chemotherapy have been published with most demonstrating benefit to the addition of hyperthermia.
These studies, while often of modest size, have shown benefit for hyperthermia in treatment of a wide
range of malignancies including glioblastoma multiforme, head and neck cancer, breast cancer,
melanoma, esophageal malignancies, and sarcoma.
Randomized Trials of Hyperthermia and Radiation CNS Malignancies
Hyperthermia has been shown to benefit patients with glioblastoma multiforme (GBM). Researchers at
the University of California at San Francisco randomized 79 patients following surgery and standard
external beam radiation therapy to 59.4 Gy to undergo an interstitial brachytherapy boost of 60 Gy with
or without interstitial hyperthermia. Time to progression and overall survival was significantly increased
with the addition of hyperthermia. Two year overall survival was 31% vs 15% with vs without
hyperthermia. A multivariate analysis adjusting for age and KPS showed that improved survival was
significantly associated with randomization to “heat” with a hazard ration of 0.51.(77)
Head and Neck Cancer

In regard to head and neck cancers, two small randomized trials have revealed benefit to addition of
hyperthermia to radiation in treatment. In one study pre-dating routine use of chemotherapy in locally
advanced head and neck cancer, 65 patients were randomized to radiation alone vs. radiotherapy and
hyperthermia. Radiation included 50 Gy in five weeks to the primary site and regional lymphatics followed by
a boost of 10 to 15 Gy to the site of gross disease. Hyperthermia was administered twice weekly.
Response as expected was excellent in either arm for patients with early stage disease with 12 of 13
experiencing complete response. For patients with stage III or IV disease complete response was increased
from 20% and 7% with radiation therapy alone to 58% and 38% respectively with addition of hyperthermia.
While the radiation therapy and lack of use of chemotherapy as applied for these patients treated in the
1980s can be rightly cited as inferior by current standards, the results are instructive in demonstrating the
ability of hyperthermia to enhance radiotherapeutic outcomes.(78)
A phase III trial in Italy from this era assessed the impact of hyperthermia when applied with radiation in
treatment of N3 squamous cell cervical lymph nodes. The primary endpoints were local control at 3 months
and acute local toxicity. A planned interim analysis inclusive of 41 patients revealed a statistically significant
difference in complete response rates in lymph nodes treated with hyperthermia. The complete response
rate in the combined arm was 82.3% compared to 36.8% with radiation alone. In light of these very positive
results the study was closed to further accrual. Treatment was also noted to be well tolerated. Apart from
skin burns generally mild in severity, acute local toxicities were similar in both groups. One patient in the
combined heat and radiotherapy arm died two months after completion of therapy with a carotid rupture
which may have been associated with extensive tumor necrosis. A longer term analysis reported actuarial 5
year overall survival of 55% vs. 0% in the hyperthermia vs. radiation alone arms.(79)
In a more recent study from India, 56 patients were randomized to receive radiation alone or with
hyperthermia for treatment of tumors of the oropharynx, hypophaynx, or larynx. Over 90% had stage 3 or 4

disease. A complete response was observed in 79% of patients randomized to hyperthermia as opposed to
42% of patients in the radiation alone arm. Survival was also significantly increased on the hyperthermia
arm to 8.0 months as compared to 4.8 months with radiation alone.(80) Notably, chemotherapy and IMRT
were not utilized, a significant number of patients in both arms did not complete the intended treatment or
were lost to follow-up, and overall outcomes were worse than expected with optimal standard therapy,
therefore limiting the conclusions that can be drawn from this study. Never-the-less overall these head and
neck trials indicate there is significant potential for hyperthermia to improve outcomes for head and neck
malignances. Thus additional study with present state-of-the-art radiation and chemotherapy is warranted.
Lung Cancer

Data in lung cancer is relatively limited given the challenges of safely heating lung without inducing
thermal damage.

An International Atomic Energy Agency (IAEA)-sponsored, multi-institutional prospective

randomized trial was, however, successfully completed.

This trial was designed to assess whether the

combination of hyperthermia and radiation improves the local response rate of locally advanced non-small cell
lung cancer (NSCLC) compared with radiation alone. 80 patients with locally advanced NSCLC were
randomized. The primary endpoint was local response rate. Secondary endpoints included local progressionfree survival and overall survival. No significant differences between the two arms with regard to local
response rate or overall survival rate was noted. However, local progression- free survival was significantly
better with the addition of hyperthermia. Toxicity was generally mild and no grade 3 late toxicity was observed
in either arm.(81)

Breast Cancer
Hyperthermia has been shown to improve complete response and local control for women with breast
cancer, particularly in the setting of recurrent chest wall disease.

Vernon reported combined

results of five randomized breast cancer trials in Europe and North America including both locally
advanced primary disease and recurrent disease for which radiation therapy was indicated and surgery
contraindicated.(82) Three distinct groups were studied: patients with inoperable primary disease, recurrent
disease in un-irradiated sites, and recurrent disease in previously radiated areas. The primary endpoint in each
trial was local tumor response.
A decision to perform a combined analysis was made after initiation of the individual studies due to slow
accrual. A prospective statistical plan was generated to allow for assessment of the initial objectives. A total
of 306 eligible patients were enrolled. Treated lesions included chest wall (71%) and intact breast tissue
(26%). 48% of cases included multiple lesions. There were a greater number of patients who had received
prior chemotherapy and lesion size was greater in the hyperthermia plus radiation treatment arm. A highly
significant difference in complete response was note for combined radiation and hyperthermia, 59%, vs.
radiation alone, 41%. On further analysis it was determined this difference was driven by benefit in patients
undergoing re-irradiation for whom radiation doses were limited. In this group there was nearly a doubling
of complete response with the addition of hyperthermia to radiation of 59% as compared to 31% with
radiation alone. Patients achieving a complete response who received hyperthermia had a reduced risk of
recurrence with hazard ratio of 0.67 compared to patients who received radiation alone. Treatment with
hyperthermia was well tolerated. Apart from acute occurrence of skin blistering of 11% vs. 2% with vs.
without hyperthermia no differences in either acute or late toxicity were noted.
Researchers at Duke University confirmed a dose response relationship for hyperthermia in a randomized
trial in which patients with superficial tumors ≤ 3 cm depth received either “low” vs “high” dose
hyperthermia combined with radiation. As prior studies had shown a thermal dose of CEM 43°C T 90 (the
number of cumulative equivalent minutes at 43°C exceeded by 90% of monitored points within the tumor)

equated with improved treatment outcome,(83-84) hyperthermia was prescribed to either CEM 43°C T90 <1 or
CEM 43°C T90 >10. 122 patients were enrolled of which 89% were determined at the time of first
hyperthermia treatment to have tumors that could be effectively heated. These 109 patients were
randomized to receive either no further hyperthermia or twice weekly hyperthermia over their course of
radiation therapy up to 10 treatments. Patients were also stratified by whether they had received prior
radiation therapy and by site of disease. Median CEM 43°C T90 in the low and high dose hyperthermia groups
was 0.74 and 14.3 respectively. 65% of patients had breast or chest wall disease, 13% head and neck, 11%
melanoma, with the remainder having various other malignancies, 36% of patients had received prior
radiation. Median radiation dose was 41 Gy in previously treated patients and 60 Gy for those not previously
irradiated.
Higher dose hyperthermia was found to be beneficial. Complete response rate in the high dose arm was 66%
and in the low HT arm 42%. The odds ratio for complete response was 2.7. This improvement in complete
response translated into improved duration of local control of 48% vs. 25% at the time of death or last followup. Previously irradiated patients had the greatest incremental gain in complete response, 23% in the no HT
arm vs. 68% in the HT arm as compared to 51% vs. 65% for patients without prior radiation therapy. The
toxicity profile was also excellent. The study therefore demonstrated that thermal dose can be prospectively
prescribed and delivered, and correlates with outcome.(85)
Pelvic Malignancies
In a multicenter trial in the Netherlands patients with locally advanced pelvic tumors were randomized to
radiation alone or radiation plus hyperthermia. 363 patients with bulky stage 1B or IIB-IVA cervical, T3 or T4
bladder or unresectable or recurrent rectal cancers were stratified based on primary disease site. With
median 2 year follow-up local control with radiation and hyperthermia vs. radiation alone was 56% vs. 39%.
3 year overall survival was significantly improved with the addition of hyperthermia, 31% vs. 24%.

On

further analysis this benefit was determined to be due to a highly significant benefit for patients with cervical
cancer with improvement in overall survival to 51% with hyperthermia compared with 27% for those
receiving radiation alone. Apart from an 11% acute rate of skin burns which resolved with conservative
treatment there were no significant differences in short or long-term toxicity.(86) Contemporaneous with
publication of these impressive results, several studies were published showing a similar benefit to the
addition of cisplatin to radiation in treatment of locally advanced cervical cancer established combined
radiation and chemotherapy as standard of care.(87) Two studies exploring potential additional benefit of
hyperthermia to both radiation and chemotherapy were subsequently initiated but closed due to poor
accrual leaving this questioned yet unanswered.

In 2010 a Cochrane review of 6 randomized controlled trials assessing radiation vs. radiation plus
hyperthermia for locally advance cervical cancer found that addition of hyperthermia was associated with
a significantly higher complete response rate with relative risk 0.56; a significantly reduced local recurrence
rate with hazard ratio 0.48; and a significantly better overall survival following the combined treatment with
HR 0.67. No increase in short or long-term toxicity was observed. The authors noted several limitations with
the data including the limited number of patients available for analysis, methodological flaws and a
significant over-representation of patients with FIGO stage IIIB (74%) which prohibited drawing definite
conclusions regarding the impact of adding hyperthermia to standard radiotherapy. They went on to note,
however, available data does suggest that the addition of hyperthermia improves local tumor control and
overall survival in patients with locally advanced cervix carcinoma without affecting treatment related grade 3
to 4 acute or late toxicity.(88)

Several randomized studies have assessed the role of the addition of hyperthermia to radiation in treatment of
rectal cancer.

Another Cochrane review identified six randomized controlled trials for rectal cancer

published between 1990 and 2007 including 520 patients evenly divided between treatment arms. Four
studies including a total of 424 patients reported overall survival rates. After 2 years, overall survival was
significantly improved with

the addition of hyperthermia with hazard ratio of 2.1 however this benefit disappeared with longer
follow-up. Five of the studies reported complete response rates with significantly higher rate of complete
response observed in the combined treatment group with relative risk of 2.8. No significant differences
were noted in acute toxicity in two studies reporting this outcome. Late toxicity was not assessed. While
these finding were promising, the authors concluded that additional studies are needed to compare
chemoradiation versus thermoradiation versus chemoradiation plus hyperthermia in high quality controlled
randomized trials.(89)

Skin Cancer
Hyperthermia has also been demonstrated to be beneficial in treatment of melanoma. The European Society
for Hyperthermic Oncology conducted a multi-center phase III trial involving 134 metastatic or recurrent
lesions of malignant melanoma in 70 patients randomly assigned to receive radiotherapy with three fractions
of 8 Gy or 9 Gy in 8 days alone or followed by hyperthermia. Addition of hyperthermia significantly increased
local control from 28% to 46%. The overall 5-year survival rate was 19%, however 38% of the patients for
whom all known disease was controlled survived 5 years demonstrating the contribution of local control to
survival.(90)
Randomized Trials of Chemotherapy and Hyperthermia Sarcoma
The European Organization for the Research and Treatment of Cancer (EORTC) in cooperation with the
European Society for Hyperthermic Oncology (ESHO) reported results of a phase III trial revealing benefit to
addition of hyperthermia to chemotherapy for treatment of sarcoma. 341 patients with either primary or
recurrent clinically localized high-risk soft-tissue sarcoma defined as ≥5cm grade 2-3, deep to the fascia were
randomized to either chemotherapy alone or combined with regional hyperthermia in

addition to local therapy. Chemotherapy consisted of 4 cycles of neoadjuvant etoposide, ifosfamide,
and doxorubicin (EIA) followed by surgery and when indicated radiotherapy to 50-60 Gy with boost up
to 66 Gy in standard fractionation followed by an additional 4 cycles of EIA. Patients randomized to
hyperthermia received hyperthermia in combination with chemotherapy on days 1 and 4 of each 3 week
chemotherapy cycle pre and post-surgery. Patient and tumor characteristics were evenly matched.
Local progression free survival, the primary endpoint, was improved at 2 years with the addition of
hyperthermia to 76% from 61% with chemotherapy alone. The hazard ration for local progression or
death with hyperthermia was 0.58. The relative hazard for disease free survival was also reduced with
hyperthermia at 0.70 with median duration of 32 vs. 18 months with vs. without hyperthermia. In a
pre-specified per protocol analysis comparing patients who completed EIA and hyperthermia vs. those
who completed EIA alone revealed an overall survival benefit with hyperthermia with hazard ratio of
0.66.(91)
Hyperthermic isolated limb perfusion for treatment of extremity soft tissue sarcomas has been assessed
in multiple phase II trials. In a recent meta-analysis of 518 patients across 12 studies, 408 had at least a
partial response and 428 had the limb spared. Median complete and partial response rates were 31%
and 55% respectively with limb sparing achieved for 83% of patients. While these results in total
were encouraging, no trial fulfilled either all ideal or essential quality criteria and seven trials did not
include statistical methodology. Therefore well designed prospective randomized trials are still warranted
to validate these findings.(92)

Bladder Cancer
Combined hyperthermia and chemotherapy has also proven beneficial in treatment of non-muscle
invasive bladder cancer. In a multicenter trial 83 patients with stage Ta and T1, grade G1 to G3
transitional cell carcinoma of the bladder were randomized to receive mitomycin C with or without

radiation therapy following complete transurethral resection. Patients with low-risk disease were
excluded. Patient and tumor characteristics were evenly matched. Freedom from tumor recurrence,
the primary endpoint was significantly improved with addition of hyperthermia to 83% as compared to
42% with mitomycin C alone.(93) In a subsequent report of long-term results, this benefit was maintained
with median follow-up for tumor free patients of 91 months. 10 disease-free survival was 53% vs. 15%
with vs. without hyperthermia.(94)
Esophageal Cancer

Researchers at Kyushu University in Japan performed a prospective randomized study exploring use of
hyperthermia with chemotherapy in treatment of esophageal cancer. From January 1988 to June 1992,
66 patients with resectable squamous cell carcinoma of the thoracic esophagus underwent preoperative
neoadjuvant therapy. 32 were treated with local hyperthermia combined with chemoradiotherapy and
while 34 patients were treated with chemoradiotherapy alone.

Over a three week period patients

received 30 Gy in fifteen fractions combined with either bleomycin 30mg twice weekly or 150mg of
cisplatin weekly with cisplatin being the primary chemotherapeutic agent from 1991 onwards.

Patients

randomized to hyperthermia received twice weekly treatments over the three week course. Patients
proceeded to undergo a sub-total esophagectomy through a right thoracotomy with lymph node
dissection 7-10 days after completion of neoadjuvant therapy. Patients characteristics were similar
between groups with 63% and 65% having stage III or IV disease and 28% and 21% presenting with nodal
disease in the hyperthermia plus chemoradiotherapy vs. radiotherapy alone groups.

Radiation

and

chemotherapy received was also similar. “Markedly effective” pathologic response, as defined by
established national guidelines was 25% and 6% and 3 year overall survival was 50% vs. 24% in the
hyperthermia plus chemoradiotherapy and chemoradiotherapy alone groups respectively.(95)

ADDITIONAL CLINICAL TRIALS

In addition to the trials described above, non-randomized phase II and earlier trials have been done for
these disease sites and others as well. While no randomized studies have been performed in prostate
cancer to date, several trials have been reported.

In a phase II trial from the Dana Farber Cancer

Institute, addition of two trans-rectal ultrasound hyperthermia treatments to radiation and androgen
deprivation was shown to be beneficial in treatment of locally advanced disease.

37 patients with

clinical T2b, T2c, or T3 disease without seminal vesicle involvement were treated with then standard
66.6 Gy and a median of 6 months of androgen deprivation therapy. Median Gleason score and PSA
were 7 and 13.3ng/ml. Patients treated on the short-term hormonal therapy arm of RTOG 92-02 were
used as historical controls. The primary endpoint was absolute two year progression free survival. The
addition of hyperthermia resulted in a significant increase in two year disease free survival of 84% as
compared with 64% for the historical control group.(96) With median follow-up of 70 months, 7 year
survival was 94% with 61% remaining free of failure. No increase in long-term toxicity was noted. Other
studies assessing use of various approaches to hyperthermia for prostate cancer have also yield
interesting results however firm conclusions are difficult to draw due to heterogeneity of patients and
treatment.(97-99)
Hyperthermic limb perfusion has been investigated in several non-randomized trials for melanoma,
many with promising results.(100-102)

These favorable findings lead the American College of Surgical

Oncology Group to include hyperthermic limb perfusion as part of standard treatment in a phase III trial
assessing melphalan with or without the addition of TNF-α.

As hyperthermia was used for all patients

as part of the standard treatment administered to both groups, insight into the specific benefit of
hyperthermia in this setting was not assessed in this phase III trial.
Whole body hyperthermia has been assessed in a limited number of phase I and II clinical studies. In a
study of 37 patients with therapy resistant metastatic or advanced solid malignancies patients

underwent treatment cycles consisting of cisplatin on day one, followed by whole body hyperthermia and
simultaneous gemcitabine 36 hours later; then a second dose of gemcitabine one week later; and daily
IFN- alpha. The protocol was well tolerated and was associated with antitumor activity in patients with a
variety of advanced metastatic solid tumors. Notably, tumor response occurred with the addition of
hyperthermia despite treating malignancies that had progressed on the same chemotherapy drugs
administered as standard treatment. In particular, good responses were observed in patients with highgrade neuroendocrine and pancreas cancers.(103)

CHALLENGES TO CLINICAL IMPLEMENTATION

Despite compelling biologic rationale and benefit demonstrated in a majority of clinical trials, the clinical
implementation of hyperthermia has been hindered by several factors. Challenges have included
logistical concerns, definition of thermal dose goals equating with outcomes, quality assurance, and
limitations of technology to deliver adequate heat.
The ability to prescribe hyperthermia and easily deliver it has been a challenge. Compared to radiation
dosing defined by physics and chemotherapy dosing defined by physiology, hyperthermia is dependent
on both physics and physiology. The body has several mechanisms to dissipate heat. While thermal
conduction and other mechanisms account for some heat dissipation, increase in blood perfusion during
hyperthermia is the primary way in which heat is removed from the targeted area. Hyperthermia
treatment is therefore more directly “hands on” as adjustments in magnitude and distribution of power
are typically necessary during hyperthermia treatment in response to changes in perfusion. This
required degree of monitoring coupled with duration of treatment typically in the range of one hour, at
therapeutic temperature tempered initial widespread enthusiasm for hyperthermia.

Quantification of thermal dose that equates with clinical outcomes has also been a challenge but one
that has been acceptably if incompletely addressed. Thermal dosimetric parameters now have been
defined from clinical trials. In particular the minimum temperatures achieved in tumor have been
shown most consistently to correlate with clinical outcome. Preclinical research on hyperthermia
revealed a breakpoint in rate of cell killing at 43°C. For each degree Celsius above 43°C the time needed
for an equivalent effect at 43°C is halved whereas for each degree Celsius below 43°C four times as
much time in needed to achieve the same extent of cell kill. A thermal dose parameter was developed to
account for both the relevance of minimum temperatures achieved and the differential rates of cell kill
at various temperatures.(104) This parameter, cumulative equivalent minutes at 43°C achieved by 90% of
the measured temperate points in the targeted area or CEM43T90, has been shown in multiple studies
to correlate with clinical outcome.(83-84,105-112)
The field of thermal dosimetry continues to evolve given that most treatment thermal profiles are based
on modest samples of temperature points in the heated region. Non-invasive approaches to
temperature measurement capable of monitoring hundreds or thousands of points in real time is now
possible albeit not widely available. Magnetic resonance imaging can be utilized using a technique
referred to as proton resonance frequency shift (PRF) which uses the correlation of proton resonance in
water with temperature to monitor heating non-invasively.(113) Other techniques utilizing ultrasound or
computed tomography are also being developed. Advances in non-invasive thermometry providing
more complete thermal profiles promise to further understandings of clinically relevant thermal dose
parameters.
The need for quality assurance guidelines became readily apparent with the conduction of early clinical
trials. In response to challenges identified from these early clinical trials, leading organizations including
the American College of Radiology, American Society for Therapeutic Radiation and Oncology and the

Radiation Therapy Oncology Group (RTOG) published the first quality assurance guidelines in 1989.(114)
The authors of the report noted several problems including lack of standardization in equipment,
treatment procedures, patient monitoring, and treatment documentation as available in radiotherapy.
The paper presented several recommendations including a set of test procedures necessary to ensure
proper operation of equipment, guidelines for frequency for such tests, and guidelines on quality control
procedures to be used during treatment to improve the safety, effectiveness, and reproducibility of
hyperthermia treatments. Furthermore examples of forms were presented to indicate the minimum
data that must be collected for acceptable documentation of treatment. In three follow-up papers the
RTOG published guidelines to address quality assurance issues pertaining to deep tissue.(115) RTOG
quality assurance guidelines for interstitial hyperthermia(116) and ultrasound.(117)

Recently, leading

experts in the United States published a review of the competencies and tasks used in a hyperthermia
clinic. Guidelines were provided for what the competencies specialist involved in delivery of care
including physicians, physicists and technologists need to perform multiple tasks to ensure properly
functioning equipment, appropriate patient selection, and to plan and administer hyperthermia
treatment.(118) The European Society for Hyperthermic Oncology has likewise published guidelines(119)
which were recently updated. Guidelines for the implementation of regional deep hyperthermia
treatments under strict rules of quality assurance were provided. The guidelines were based on practical
experience from several hyperthermia centers. Recommendations for hyperthermia treatments,
including indication, preparation, treatment, and standardized analysis were presented.(120)
The technological challenge of delivery of effective hyperthermia was a primary concern early on. Over
the past 35 years, several hundred devices and techniques have been developed for heating tissue.
Technology for delivery of hyperthermia has come a long way from the clinical investigations of the
1980’s. Large improvements have been made in both thermal monitoring and power control for real

time adjustment of heating distributions in the body. In many ways, advances in treatment planning
and delivery for hyperthermia have paralleled advances in radiation therapy over this time.
Initially, clinicians attempted to treat tumors of widely varying size and location within the body using a
limited set of fixed dimension “one size fits all” equipment that eventually proved to offer limited or no
adjustability to accommodate individual tumor heating requirements. Equipment available for the initial
clinical trials of hyperthermia used simple non-adjustable applicators that could effectively treat only
volumes 3-4 cm diameter with excessive heating in the center of the field and rapid fall off at the edges.
Second generation equipment began to appear in the 1990’s with multi-aperture planar arrays and wellintegrated computer monitoring and control interfaces that provided improved thermal feedback. Basic
treatment planning capabilities became available with 2-D generic tissue treatment planning to enable
adjustment of heating patterns to fit a larger number of tumors. Over the past 10 years, the field has
taken a significant leap forward. Several site-optimized applicators have been developed. These multielement phase and/or amplitude adjustable arrays are often combined with increasingly
sophisticated treatment planning programs based on clinically realistic matching patient anatomic
models. Improved real time thermal feedback is increasingly available. Techniques include use of
mobile thermal mapping probes or non-invasive magnetic resonance image based volumetric
temperature distribution monitoring during treatment.
FUTURE DIRECTIONS
Evolving areas of growth for hyperthermia include application of the principles of radio- and
chemosensitization to thermal ablation, furthering the development of strategies for heat induced
targeted drug delivery, definition of clinical strategies that take advantage of the tumor specific immune
response that occurs with hyperthermia, and commercialization/distribution of new devices to enable
treatment of a larger number of tumor sites.

While thermal ablation is typically used alone, a heated

but not ablated rim of tissue exists around the high temperature region which provides opportunity for
enhanced tumor kill with radiation or chemotherapy. Moving forward from more complicated
treatment approaches such as isolated limb perfusion, thermally sensitive liposomes and a range of
nanoplatforms which facilitate release of encapsulated drug in a tightly defined temperature range are
either under development or in some cases undergoing clinical investigation as methods to enhance
chemotherapeutic effect. Thermally enhanced immunotherapy is a therapeutic strategy that awaits
development. While there are several questions that need to be answered including timing,
sequencing, and optimal dosing with immune therapies and radiation, the potential for hyperthermia to
play a role in the rapidly growing field of oncologic immunotherapy is clear and warrants investigation.
Lastly, continued advancement of technology akin to the advances in radiation planning, delivery, and
monitoring are moving forward including more automated treatment delivery and comprehensive real
time non-invasive thermometry.

CONCLUSIONS
The potential for hyperthermia to benefit cancer patients has long been recognized. New appreciation
for the biologic and physiologic mechanisms through which hyperthermia may improve outcomes of
radiation and chemotherapy treatments led to enthusiasm in the 1980’s that subsequently waned due
to technical limitations and the need to develop clinical standards for heat delivery. Despite these early
challenges clinical trials for a wide range of malignancies have been completed with the vast majority
indicating clinical benefit. Technology for heat delivery, standards for quality assurance and thermal
biology have all significantly advanced in the 35 years since hyperthermia was introduced into the
modern cancer clinic.

Coupled with timely opportunities to advance multi-disciplinary cancer care

through combination with state-of-the-art radiation, chemotherapy, and immunotherapy, renewed
focus on hyperthermia in oncology is warranted by the broad cancer community.
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